Literature DB >> 19086329

Hepatitis C patients' self-reported adherence to treatment with pegylated interferon and ribavirin.

J J Weiss1, L Bhatti, D T Dieterich, B R Edlin, D A Fishbein, M B Goetz, K Yu, G J Wagner.   

Abstract

BACKGROUND: Prior research on adherence to hepatitis C treatment has documented rates of dose reductions and early treatment discontinuation, but little is known about patients' dose-taking adherence. AIMS: To assess the prevalence of missed doses of pegylated interferon and ribavirin and examine the correlates of dose-taking adherence in clinic settings.
METHODS: One hundred and eighty patients on treatment for hepatitis C (23% coinfected with HIV) completed a cross-sectional survey at the site of their hepatitis C care.
RESULTS: Seven per cent of patients reported missing at least one injection of pegylated interferon in the last 4 weeks and 21% reported missing at least one dose of ribavirin in the last 7 days. Dose-taking adherence was not associated with HCV viral load.
CONCLUSIONS: Self-reported dose non-adherence to hepatitis C treatment occurs frequently. Further studies of dose non-adherence (assessed by method other than self-report) and its relationship to HCV virological outcome are warranted.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19086329      PMCID: PMC2891196          DOI: 10.1111/j.1365-2036.2008.03718.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  19 in total

1.  A comparison study of multiple measures of adherence to HIV protease inhibitors.

Authors:  H Liu; C E Golin; L G Miller; R D Hays; C K Beck; S Sanandaji; J Christian; T Maldonado; D Duran; A H Kaplan; N S Wenger
Journal:  Ann Intern Med       Date:  2001-05-15       Impact factor: 25.391

2.  HIV and liver disease forum: conference proceedings.

Authors:  Kenneth E Sherman; Marion Peters; Margaret James Koziel
Journal:  Hepatology       Date:  2007-06       Impact factor: 17.425

Review 3.  Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel.

Authors:  Vincent Soriano; Massimo Puoti; Mark Sulkowski; Antonietta Cargnel; Yves Benhamou; Marion Peters; Stefan Mauss; Norbert Bräu; Angelos Hatzakis; Stanislas Pol; Juergen Rockstroh
Journal:  AIDS       Date:  2007-05-31       Impact factor: 4.177

4.  Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C.

Authors:  Mitchell L Shiffman; Marc G Ghany; Timothy R Morgan; Elizabeth C Wright; Gregory T Everson; Karen L Lindsay; Anna S F Lok; Herbert L Bonkovsky; Adrian M Di Bisceglie; William M Lee; Jules L Dienstag; David R Gretch
Journal:  Gastroenterology       Date:  2006-11-11       Impact factor: 22.682

5.  Provider assessment of adherence to HIV antiretroviral therapy.

Authors:  D R Bangsberg; F M Hecht; H Clague; E D Charlebois; D Ciccarone; M Chesney; A Moss
Journal:  J Acquir Immune Defic Syndr       Date:  2001-04-15       Impact factor: 3.731

6.  Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.

Authors:  M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321

7.  Limited uptake of hepatitis C treatment among injection drug users.

Authors:  Shruti H Mehta; Becky L Genberg; Jacquie Astemborski; Ravi Kavasery; Gregory D Kirk; David Vlahov; Steffanie A Strathdee; David L Thomas
Journal:  J Community Health       Date:  2008-06

8.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

Authors:  Michael W Fried; Mitchell L Shiffman; K Rajender Reddy; Coleman Smith; George Marinos; Fernando L Gonçales; Dieter Häussinger; Moises Diago; Giampiero Carosi; Daniel Dhumeaux; Antonio Craxi; Amy Lin; Joseph Hoffman; Jian Yu
Journal:  N Engl J Med       Date:  2002-09-26       Impact factor: 91.245

9.  Assessing the validity of self-reported medication adherence in hepatitis C treatment.

Authors:  Scott R Smith; Abdus S Wahed; Stephanie S Kelley; Hari S Conjeevaram; Patricia R Robuck; Michael W Fried
Journal:  Ann Pharmacother       Date:  2007-05-22       Impact factor: 3.154

10.  How well do clinicians estimate patients' adherence to combination antiretroviral therapy?

Authors:  Loren G Miller; Honghu Liu; Ron D Hays; Carol E Golin; C Keith Beck; Steven M Asch; Yingying Ma; Andrew H Kaplan; Neil S Wenger
Journal:  J Gen Intern Med       Date:  2002-01       Impact factor: 5.128

View more
  14 in total

1.  Relationship between adherence to hepatitis C virus therapy and virologic outcomes: a cohort study.

Authors:  Vincent Lo Re; Valerie Teal; A Russell Localio; Valerianna K Amorosa; David E Kaplan; Robert Gross
Journal:  Ann Intern Med       Date:  2011-09-20       Impact factor: 25.391

2.  Adherence to PEG/ribavirin treatment for chronic hepatitis C: prevalence, patterns, and predictors of missed doses and nonpersistence.

Authors:  D M Evon; D A Esserman; J E Bonner; T Rao; M W Fried; C E Golin
Journal:  J Viral Hepat       Date:  2013-02-25       Impact factor: 3.728

Review 3.  Chronic hepatitis C and antiviral treatment regimens: where can psychology contribute?

Authors:  Donna M Evon; Carol E Golin; Michael W Fried; Francis J Keefe
Journal:  J Consult Clin Psychol       Date:  2012-06-25

4.  Self-efficacy and adherence to antiviral treatment for chronic hepatitis C.

Authors:  Jason E Bonner; Denise A Esserman; Carol E Golin; Donna M Evon
Journal:  J Clin Gastroenterol       Date:  2015-01       Impact factor: 3.062

5.  Impact of hepatitis C treatment initiation on adherence to concomitant medications.

Authors:  Maria Pizzirusso; Jenny Lin; Cory Head; Sue M Marcus; Samia Ahmed; Norbert Bräu; Jeffrey J Weiss
Journal:  J Assoc Nurses AIDS Care       Date:  2013-09-24       Impact factor: 1.354

6.  Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users.

Authors:  Jason Grebely; Gail V Matthews; Margaret Hellard; David Shaw; Ingrid van Beek; Kathy Petoumenos; Maryam Alavi; Barbara Yeung; Paul S Haber; Andrew R Lloyd; John M Kaldor; Gregory J Dore
Journal:  J Hepatol       Date:  2010-11-23       Impact factor: 25.083

7.  Adherence to hepatitis C virus therapy in HIV/hepatitis C-coinfected patients.

Authors:  Vincent Lo Re; Valerie Teal; A Russell Localio; Valerianna K Amorosa; David E Kaplan; Robert Gross
Journal:  AIDS Behav       Date:  2013-01

8.  Self-reported treatment adherence in inflammatory bowel disease in Indian patients.

Authors:  Jay Bhatt; Samir Patil; Anand Joshi; Philip Abraham; Devendra Desai
Journal:  Indian J Gastroenterol       Date:  2009-11-24

9.  Adherence to hepatitis C virus therapy and early virologic outcomes.

Authors:  Vincent Lo Re; Valerianna K Amorosa; A Russell Localio; Rose O'Flynn; Valerie Teal; Zachariah Dorey-Stein; Jay R Kostman; Robert Gross
Journal:  Clin Infect Dis       Date:  2009-01-15       Impact factor: 9.079

Review 10.  Review article: adherence to medication for chronic hepatitis C - building on the model of human immunodeficiency virus antiretroviral adherence research.

Authors:  J J Weiss; N Bräu; A Stivala; T Swan; D Fishbein
Journal:  Aliment Pharmacol Ther       Date:  2009-03-26       Impact factor: 8.171

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.